Open access

Social Anxiety Disorder

Written By

Nesrin Dilbaz, Aslı Enez and Serçin Yalçın Çavus

Submitted: 03 November 2010 Published: 12 September 2011

DOI: 10.5772/19367

From the Edited Volume

Different Views of Anxiety Disorders

Edited by Salih Selek

Chapter metrics overview

4,793 Chapter Downloads

View Full Metrics

1. Introduction

1.1. Epidemiology of social anxiety disorder (SAD)

SAD, also known as social phobia, is characterised by excessive fear of embarrassment or humiliation in social situations, which in turn leads to marked distress or avoidance of these situations and functional impairment as described in DSM-IV-TR.

It is a common disorder with early onset, significant comorbidity and functional impairment (Meron Ruscia et al., 2008).

SAD has been ranked as one of the top ten chronic disorders – mental or physical – in terms of its effects on objective outcomes, such as days of work lost and reduced health-related quality of life (Alonso, 2004). According to the National Comorbidity Survey, SAD is the most reported anxiety disorder and has a lifetime prevalence of 12% (Kessler et al., 2005), with considerable coexisting psychiatric disorders, such as depression, anxiety, and substance-related disorders.Lifetime prevalence of social anxiety disorder among Turkish university students was 23% (Dilbaz 2006). Co-occurring SAD and depression carry a substantial risk of suicide, which further complicates treatment (Beesdo et al., 2007; Thase, 2007). SAD symptoms normally emerge during early adolescence and continue throughout adulthood; they affect women more often than men (Fehm et al., 2005).In clinical samples the ratio of male and female changes in the favour of males. (Dilbaz and Güz 2002). Trials suggest that social anxiety even below the diagnostic threshold is clearly associated with adverse outcomes like elevated risk for comorbid disorders and associated with impairment in diverse areas of life.

Despite the growing understanding of this condition, information is lacking on key aspects of the disorder and many individuals, including doctors, psychiatrists and patients, unaware about this condition.

1.2. Children and adolescents

SAD, which so often begins in childhood, precedes other comorbid disorders and may be a direct or indirect risk factor for other disorders, such as depression and substance abuse. Epidemiologic findings show that in the pediatric primary healthcare setting anxiety disorders are very common ranging from 1% to 10% (Briggs-Gowan et al., 2000; Busch et al., 2002; Costello, 1989), but are unrecognized and under-treated (Chavira et al., 2004; Wren et al., 2003). In community settings, rates of SAD in youth range from 0.5% to 4% (Essau et al., 1999; Wittchen et al., 1998) and from 3% to 6.8% in primary care settings (Busch et al., 2002; Costello, 1989; Chavira et al., 2004). Recent research suggest that lifetime prevalence rates in adolescents in the US and Germany are between 5% and 15% (Heimberg et al., 2000; Lewinsohn et al., 1993). Although the age of onset is usually in the early teens with a mean age of onset of 15.5 years (Schneider et al., 1993) children as young as 8 years old have been diagnosed with the disorder (Beidel & Turner, 1998).

Shyness, behavioral inhibition and selective mutism can be considered in spectrum of social anxiety disorder in childhood. Children who are rated by their parents as having a shy temperament in infancy or in early childhood had an approximately 2 or 3 times increased probability of having an anxiety disorder in adolescence (Prior et al, 2000). In a five year longitudinal study, researchers found that behavioral inhibition-which can be described as a tendency to demonstrate fearfulness or resistance when faced with an unfamiliar stimuli, in pre-school children appeared to be a predictor for social anxiety in middle school (Hirshfeld-Becker et al., 2007). Selective mutism can be considered an extreme form of social anxiety including features of shyness and behavioral inhibition, where the most prominent feature is the inhibition of speech in select situations. Comorbidity rates between selective mutism and social anxiety disorder range from 70–95% (Dummit et al., 1997; Black & Uhde, 1995) and characteristics such as shyness, anxiousness, withdrawal and seriousness are used to describe both selective mutism and social anxiety alike (Steinhausen & Juzi, 1996; Kumpulainen et al., 1998).

Studies have shown that in children aged 7–13 years with SAD, 60% had an additional psychiatric diagnosis, of whom 36% had an anxiety disorder as follows: generalized anxiety disorder 10%; attention deficit hyperactivity disorder 10%; specific phobia 10%; and selective mutism 8% (Biedel et al., 1999). Those individuals who develop comorbid disorders will also have an increased risk of suicidal ideation and suicide attempts.

In treatment of social anxiety disorders in childhood and adolecence, most practitioners advise the initial use of psychological interventions followed by pharmacotherapy when necessary. Specific treatments have employed cognitive-behavioral group therapy for SAD in adolescents, social effectiveness therapy for children (Beidel et al., 2000) and ‘coping cat’ child behavior therapy (Flannery-Schroeder et al., 2000). Overall, most clinical researchers now believe that CBT is the treatment of choice for youth with internalizing disorders including SAD (March et al., 2003).

There are very few pharmacotherapy trials in general and even fewer randomized, double-blind, placebo-controlled trials in childhood anxiety disorders. Studies with both open-label and double blind placebo control groups have shown promising results ranging from 36–100% success rates (Compton et al., 2001; Mancini et al., 1999). Selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) are defined as first line pharmacotherapy for social anxiety disorders in youth with a careful assessessment of suicidal ideation before starting these antidepressants.

The development of comorbid mental disorders such as depression and substance abuse, children and adolescents with this illness are at risk for educational or occupational under-achievement, and failure to achieve financial and emotional independence. The challenge of preventing the consequences of SAD lies in early diagnosis.


2. Organic etiology of SAD

Although the etiology of SAD is poorly understood, emerging evidence indicates multidimensional causes. It is a distinct psychiatric disorder with genetic underpinnings and is associated with neurobiological and environmental mechanisms.

Over the past two decades, numerous neurobiological methods have been used in studies of SAD including structural, functional and receptor brain imaging, pharmacological trials, candidate gene investigations and studies of psychophysiological, endocrine, biochemical and behavioral responses to stressful challenges. It has been hypothesized that affect regulation is compromised in individuals with SAD, either due to hyperactivity in emotion triggering areas like the amygdala and insula, or hypoactivity in modulatory regions like the anterior cingulate and prefrontal cortices. It also has been hypothesized that SAD patients would show exaggerated amygdala responses to angry or threatening faces in comparison to healthy control subjects and that amygdala hyperresponsivity is associated with enhanced fear conditionability in SAD (Furmark, 2009).

A range of neurotransmitters may be important in SAD including the monoamines, glutamate, GABA, and several neuropeptides, but to date, the serotonergic and dopaminergic transmission systems have received most of the attention.

Serotonin has been implicated in animal models of fear and anxiety (Graeff, 2002) and the therapeutic efficacy of SSRIs (Ipser et al., 2008) strongly suggests that serotonin has a crucial role in SAD. Allelic variation in serotonin-related genes modulate amygdala responsivity both in healthy volunteers (Hariri & Holmes, 2006) and in patients with SAD (Furmark et al., 2004). Lanzenberger et al. demonstrated a significantly lower serotonin-1A receptor binding potential in SAD patients relative to controls in the amygdala, anterior cingulate cortex, insula, and dorsal raphe nuclei in their PET study (Lanzenberger et al., 2007). Serotonergic involvement is also supported by neuroendocrine challenges studies (Tancer, 1993).

Dopamine is known to play a central role in motivation and reward-seeking behaviors and several lines of evidence point to a dysfunction of this transmitter system in SAD like patients with Parkinson’s Disease, which is associated with dopamine hypofunction, appear to have enhanced risk for developing SAD (Richard et al., 1996). Abnormal central dopaminergic neurotransmission has also been reported in animal trials relevant to SAD, such as studies of social subordination in primates (Grant et al., 1998). Two independent SPECT studies also point directly to an altered dopamine system activity in SAD. Tiihonen et al. reported that the striatal dopamine reuptake site density was markedly lower in patients with SAD than controls, presumably reflecting a smaller number of dopaminergic synapses and neurons in the basal ganglia (Tiihonen et al., 1997). Schneier et al. also observed that striatal dopamine D2 receptor binding was significantly lower in subjects with SAD than in comparison subjects (Schneier et al., 2000).

Genetically-oriented studies of SAD and related constructs such as behavioral inhibition, neuroticism, introversion and harm-avoidance suggest that genetic factors play at least a moderate role in the etiology of excessive social anxiety (Stein et al., 1994). The short (s) allele of the promoter polymorphism of the human serotonin transporter gene (the 5-HTT-linked polymorphic region; 5-HTTLPR) has been associated with anxiety-related personality traits, increased fear conditionability, and life-stress-induced aff ective disorder (Serretti et al., 2006). Several other genotypes influence amygdala responsivity and could thus be considered in future studies of SAD, for example the tryptophan hydroxylase-2 gene (G-703T polymorphism) (Brown et al., 2005) and the catechol-Omethyltransferase gene (COMT Val158Met) (Smolka et al., 2005).


3. Diagnosis and assessment of SAD

The first challenge in the treatment of SAD is making a correct diagnosis. There is evidence that SAD is under-diagnosed and under-treated in primary care and specialist settings alike (Katzelnick & Greist, 2001). Possible reasons for this may be lack of diagnostic awareness, lack of diagnostic threshold clarity or the presence of co-morbid disorders. Moreover, as consultation with a clinician may be perceived as social interaction, the nature of the disorder may cause patients to delay seeking help, and when they eventually do, it is often with physical complaints or psychiatric comorbidity.

During the initial evaluation it is important to find out severity of symptoms as well as the degree of avoidance and functional impairment present. Rating scales such as the Liebowitz social anxiety scale that is translated and validated to Turkish also, may be helpful in assessing both feared situations and avoidance and can be used to monitor the patient’s treatment progress (Liebowitz 1987, Dilbaz and Guz ). A range of other SAD scales are also available, like the Brief Social Phobia Scale (clinician rated) and the Social Phobia Inventory (patient rated) (Davidson et al., 1997; Conner et al., 2000).


4. Co-morbidity

Significant comorbidity of social anxiety and mood disorders have been consistently shown in the literature (Kessler et al., 1999; Lecrubier & Weiller, 1997; Pini et al. 1997). Social anxiety has also been linked to severity (Merikangas & Angst, 1995) and persistence (Alpert et al. 1997) of mood disorders. Also comorbid mood disorders have worsen social anxiety symptoms and result in greater impairment in patients with SAD (Erwin et al., 2002). A significant number of patients presenting with social anxiety will have a secondary anxiety disorder, particularly panic disorder with agoraphobia and generalized anxiety disorder (Mennin et al. 2000, Schneier et al., 1992). Comorbid depressive or anxiety disorders complicate SAD, the severity of symptoms and suicidality should be assessed and hospitalisation considered if indicated. In such cases, the treatment of choice should ideally target both the mood and the anxiety components.

Social phobia and avoidant personality disorder were introduced in the DSM classification system nearly 30 years ago. Since then it has been shown that these two disorders can be found highly comorbid in patients, in some trials as high as 89% (Schneier et al., 1991). Some researchers have interpreted this high rate of overlap to mean that social phobia and avoidant personality disorder reflect a spectrum of social anxiety (Tillfors & Ekselius, 2009).

Social anxiety disorder is associated with high rates of alcohol use disorders (Morris et al., 2005). Almost half of the patients with lifetime SAD meet criteria for lifetime prevalence of an alcohol use disorder (Grant et al.,2005) and it is a significantly high rate when compared to general population. Among the anxiety disorders, SAD shows a particularly problematic risk profile for comorbid alcohol use disorders, as SAD is associated with higher rates of alcohol use disorders relative to most other anxiety disorders (Kessler et al.,1997).

Recently, researchers have identified that individuals with SAD appear particularly vulnerable to marijuana-related problems too. Data from the National Comorbidity Study suggest that individuals with SAD are 7 times more likely to experience marijuana dependence relative to the general population (Agosti et al, 2002) and undergraduates with higher social anxiety appear to be particularly vulnerable to marijuana use problems (Buckner et al, 2007; Buckner et al., 2008a). In a study, adolescents with SAD were nearly 5 times more likely to develop marijuana dependence as young adults compared to adolescents without SAD (Buckner et al., 2008b).


5. Treatment of SAD

Current recommended treatment options for social anxiety disorder include pharmacotherapy and cognitive behavioural therapy (CBT). (Dilbaz 2005) Although several randomised controlled trials (RCTs) have failed to show efficacy for β-adrenoceptor antagonists in generalised SAD, it has been suggested that these agents may be useful in non-generalised SAD, patients with performance anxiety only. Efficacy in the treatment of generalised SAD has been demonstrated for a number of interventions, (Stein, 2003; Blanco et al., 2003) including SSRIs, high potency benzodiazepines (e.g. clonazepam), MAOIs (e.g. phenelzine), reversible inhibitors of monoamine oxidase A (MAO-A) [RIMAs, e.g. moclobemide], certain antiepileptics (e.g. gabapentin, pregabalin), serotonin-noradrenaline reuptake inhibitors (venlafaxine) and CBT (Zaider & Heimberg 2003).

5.1. Nonpharmacological treatments

These treatments include exposure, cognitive re-structuring, relaxation techniques and social skills training, often used in combination. Literature have concluded that cognitive behavioral therapy (CBT) is often effective for treating social anxiety disorder. The goal of cognitive behavioral therapy (CBT) is to provide techniques and practice to patients with social anxiety disorder, so they can learn to change how they think about and behave in situations that terrify them. CBT may be offered individually or as part of group therapy. There is continued interest in the question of whether group or individual treatment is more effective. Early studies suggested some superiority for group treatment (Wlazlo et al., 1990), and arguments were raised that the group setting would provide a richness of exposure experiences not easily replicated in individual treatment; by the late 1990s the weight of evidence suggested that there was no clear superiority between group and individual treatment (Gould et al., 1997).

Meta-analyses of the efficacy of CBT for SAD that have compared various types of CBT with each other and with control conditions have yielded the highest effect sizes for exposure-based interventions (Federof & Taylor, 2001; Hope et al.,1995). In exposure therapy, the type of CBT most often used and studied for social anxiety disorder, therapists gradually expose patients to the dreaded situation and suggest ways to manage fear. The exposure-based extinction of fear is now thought to involve new learning that actively inhibits the fear reaction to a given cue (Davis et al., 2006). In other variations of CBT— not as well studied as exposure therapy— patients learn and practice social skills and relaxation techniques.

5.2. Pharmacological treatments

SSRIs; evidence from RCTs supports that the efficacy and tolerability of almost all SSRIs (escitalopram (Stein et al.,2005), fluvoxamine, (Van Vliet et al.,1994; Stein et al., 1999) paroxetine, (Liebowitz et al., 2002; Baldwin et al., 1999; Stein et al., 1998) sertraline (Katzelnicket al., 1995; Liebowitz et al., 2003), fluoxetin (Black et al., 1992), citalopram (Bouwer & Stein, 1998) in the treatment of SAD, so SSRIs can be regarded as first-line treatment in SAD. These agents have the additional benefit of treating comorbid conditions commonly seen with SAD (Van Ameringen et al., 2004). Fluoxetine, fluvoxamine and sertraline have been the most studied SSRIs in socially phobic children and adolescents and have shown good efficacy and tolerability in this group (Robinson & Hood, 2007).

Venlafaxine; has shown promising results in open-label and controlled trials in the treatment of SAD. Venlafaxine is an effective treatment option for generalised social anxiety disorder but has no superiority from paroxetine in clinical trials (Allgulander et al., 2004; Liebowitz et al., 2005). While venlafaxine is an effective treatment, this may be related to its serotonergic profile, and the authors are unimpressed with response to the specific noradrenergic agent reboxetine from both the literature and clinical experience. Venlafaxine is associated with significant side effects and discontinuation syndrome and described as second-line treatments of social anxiety in most settings (Robinson & Hood, 2007).

MAOIs; Phenelzine was one of the first established treatments for SAD with several early double-blind, placebo-controlled trials demonstrating efficacy in this disorder (Versiani et al., 1992; Gelernter et al., 1991). In light of their adverse effect profiles and the dietary restrictions associated with use of these agents, together with the availability of alternative treatments, MAOIs are currently not considered to be a first-line treatment for SAD.

RIMAs; reversible inhibitors of monoamine oxidase A, appears inferior to that of phenelzine in efficacy but the main advantages of moclobemide over phenelzine are superior tolerability and no concern about dietary restrictions at the standart dosage of 600 mg/day moclobemide. This may be a particularly important consideration in the long-term treatment of SAD (Stein et al., 2002).

Benzodizepines, despite the positive results, the adverse effect profile, the potential for dependence, the possibility of rebound anxiety, the possible negative consequences of state-dependent learning and their ineffectiveness in the treatment of depression shows that these agents should not be considered as first-line monotherapy for SAD (Jackson 1995; Keith et al., 2003).

Beta Blockers; Beta-blockers are effective at blocking peripheral autonomic symptoms such as tachycardia, tremor, sweating, blushing and dry mouth and thus have a potential role as anxiolytics. They are effectively used in the treatment of performance anxiety but there is substantial evidence that beta-blockers are not effective in social phobia (Liebowitz et al., 1992; Turner et al., 1994) and that better options are available. A limited role in performance anxiety is indicated.

Gabapentine, Pregabalin and Levetirasetam; Some anticonvulsants trials suggest that gabapentin, pregabalin and levetirasetam could be alternative agents for patients who are nonresponsive to SSRIs and SNRIs (Pande et al., 1999; Pande et al., 2004; Zhang et al., 2005). However these agents need further studies about the safety and efficacy in SAD.

Other pharmacological agents for treatment of SAD; Tricyclic antidepressants have been used but failed to be an effective treatment choice for social anxiety disorder (Emmanuel et al., 1997; Simpson et al., 1998). There are trials with buspirone in literature but these trials have both negative and positive outcomes in social anxiety disorder. So that buspirone may be a useful agent for augmentation in social anxiety disorder (Robinson & Hood, 2007 ). There is a little evidence for bupropion efficacy in social phobia (Emmanuel et al., 2000). There are trials that have found mirtazapine as an effective treatment option for social anxiety disorder (Mrakotsky et al., 2007; Mörtberg, 2006). However in a recent study mirtazapine showed no superiority to placebo for treatment of SAD (Shutters et al., 2010).

Atypical antipsychotics have been shown to have anxioloytic properties in the literature (Depping et al., 2010; Vulink et al., 2011). Olanzapine (Barnett et al., 2002) and quetiapine (Vaishavi et al., 2007) have been found effective as monotherapy in the treatment of SAD. In another study switchover to aripiprazole effectively improved social anxiety in patiets with schizophrenia (Stern et al., 2009).

5.3. Inadequate response to pharmacotherapy and augmentation strategies

Criteria for remission of SAD proposed by Ballenger (Ballenger, 2001) include absence of core symptoms of SAD, no or minimal anxiety (e.g. in anticipation of social interaction) as rated by rating scales such as the Hamilton Rating Scale for Anxiety, no functional impairment (the Sheehan Disability Scale may be used to evaluate this), (Sheehan et al., 1996) and remission of course of action when first-line treatment with a co-morbid depression as reflected by the Hamilton Rating Scale for Depression. It should, however, be noted that the mean reduction in Liebowitz Social Anxiety Scale scores was <50% in a review of 19 double-blind, placebo-controlled trials involving patients with SAD. Switching to another SSRIs, venlafaxine or MAOIs has been suggested in non responders or patients with adverse event. Augmentation strategies that may prove useful in partial treatment responders include buspirone, clonazepam, gabapentin, bupropion or new generation antipsychotics, although empirical data are lacking (Barnett et al., 2002; Schutters et al., 2005; Pallanti et al., 1999).

In case of comorbidity moclobemide was found to be effective and well-tolerated in the SAD patients with anxiety disorders as well as SSRIs. In the presence of co-morbid alcohol abuse, MAOIs and benzodiazepines can complicate the treatment, SSRIs have usefulness in reducing the alcohol consumption (Naranjo & Knoke, 2001). CBT may be the treatment of choice during pregnancy and lactation.


6. Conclusion

SAD is a prevalent and disabling disorder that often remains undetected unless the clinicaian takes a careful history. Present consensus supports that SSRIs can currently be regarded as first-line treatment in SAD because of their proven efficacy, tolerability and bility to treat co-morbid conditions such as depression or other anxiety disorders (Stein, 2003; Blanco et al., 2003; Ballenger et al., 1998). There is a recent evidence venlafaxine XR may also be considered in the first-line. Second-line treatments include MAOIs (e.g. phenelzine) and RIMAs (e.g.moclobemide).

The combination of CBT and an SSRI is often espoused as best practice, unfortunately there is little hard evidence supporting this (despite considerable face validity). Future studies taking a good look at combination therapies of this type are encouraged and also future research should focus on complicated and treatment refractory SAD and treatment strategies in special populations (e.g.children and adolescents).


  1. 1. Agosti V. Nunes E. Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 2002 28 643 652
  2. 2. Allgulander C. Mangano R. Zhang J. et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel group comparison with paroxetine. Hum Psychopharmacol 2004 19 387 396
  3. 3. Alonso J. Angermeyer M. C. Bernert S. Bruff aerts. R. Brugha T. S. Bryson H. de Girolamo G. Graaf R. Demyttenaere K. Gasquet I. Haro J. M. Katz S. J. Kessler R. C. Kovess V. Lepine J. P. Ormel J. Polidori G. Russo L. J. Vilagut G. Almansa J. Arbabzadeh-Bouchez S. Autonell J. Bernal M. MA Buist-Bouwman Codony. M. Domingo-Salvany A. Ferrer M. Joo S. S. et al. Disability and quality of life impact of mental disorders in Europe. Acta Psychiatr Scand Suppl 2004 420 38 46
  4. 4. Alpert J. E. Uebelacker L. A. Mc Lean N. E. AA Nierenberg Pava. J. A. Worthington J. J. I. I. I. Tedlow J. R. Rosenbaum J. F. Fava M. Social phobia. avoidant personality. disorder atypical depression. co-occurrence clinical implications. Psychological Medicine 1997 27 627 633
  5. 5. Baldwin D. Bobes J. Stein D. J. et al. Paroxetine in social phobia- social anxiety disorder: randomised, double blind, placebo-controlled study. Br J Psychiatry 1999 175 120 6
  6. 6. Ballenger J. C. Davidson J. A. Lecrubier Y. et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 1998Suppl.): 54S-60S.
  7. 7. Ballenger JC.Treatment of anxiety disorders to remission. J Clin Psychiatry 2001Suppl. 12: 5S-9S.
  8. 8. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR.Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol 2002 16 365 368
  9. 9. Beesdo K. Bittner A. Pine D. S. Stein M. B. Höfler M. Lieb R. et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Archives of General Psychiatry 2007 64 903 912
  10. 10. Beidel DC, Turner SM, Morris TL.Behavioral treatment of childhood social phobia. J Consult Clin Psychol 2000 68 1072 80
  11. 11. Beidel DC, Turner SM, Morris TL.Psychopathology of childhood social phobia. J Am Acad Child Adolesc Psychiatry 1999Suppl. 6 643 50
  12. 12. Beidel DC, Turner SM. Shy children, phobic adults: nature and treatment of social phobia.Washington, DC: American Psychological Association, 1998
  13. 13. Black B. Uhde T. W. ME Tancer Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 1992 12 293 5
  14. 14. Black B. Uhde T. W. Psychiatric characteristics of children with selective mutism: a pilot study. J Am Acad Child Adolesc Psychiatry 1995 34 847 856
  15. 15. Blanco C. Schineider F. R. Schmidt A. et al. Pharmacological treatment of social anxiety disorder:a meta-analysis. Depress Anxiety 2003 18 1 29 40
  16. 16. Bouwer C. Stein D. J. Use of the selective serotonin reuptake and inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998 49 79 82
  17. 17. MJ Briggs-Gowan Horwitz. S. M. Schwab-Stone M. et al. Mental health in pediatric settings: distribution of disorders and factors related to service use. J Am Acad Child Adolesc Psychiatry 2000 39 841 9
  18. 18. Brown S. M. Peet E. Manuck S. B. Williamson D. E. Dahl R. E. Ferrell R. E. Hariri A. R. A. regulatory variant. of the. human tryptophan. hydroxylase gene biases. amygdala reactivity. Mol Psychiatry 2005 10 884 888
  19. 19. Buckner JD, Bonn-Miller MO, Zvolensky MJ et al., 2007, Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav; 32 2238 2252
  20. 20. Buckner JD, Schmidt NB, Lang AR et al.Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 2008a 42 230 239
  21. 21. Buckner JD, Schmidt NB. Marijuana effect expectancies: relations to social anxiety and marijuana use problems.Addict Behav 2008b 33 1477 1483
  22. 22. Busch B. Biederman J. Cohen L. et al. Correlates of. A. D. H. D. among children. in pediatric. psychiatric clinics. Psychiatr Serv 2002 53 1103 11
  23. 23. Chavira D. A. Stein M. B. Bailey K. et al. Child anxiety in primary care: prevalent but untreated.Depress Anxiety 2004 20 155 64
  24. 24. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS.Sertraline in children and adolescents with social anxiety disorder: An open trial. J Am Acad Child Adolesc Psychiatry 2001 40 5 564 571
  25. 25. Connor KM, Davidson JRT, Churchill LE, et al.Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale. Br J Psychiatry 2000 176 379 86
  26. 26. Costello EJ.Child psychiatric disorders and their correlates: a primary care pediatric sample. J Am Acad Child Adolesc Psychiatry 1989 28 851 5
  27. 27. Davidson J. R. Miner C. M. De Veaugh-Geiss J. et al. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997 27 1 161 6
  28. 28. Davis M. Myers K. M. Chhatwal J. Ressler K. J. Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx 2006
  29. 29. Depping A. M. Komossa K. Kissling W. Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010CD008120.
  30. 30. Dummit ESI, Klein RG, Tancer NK, et al.Systematic assessment of 50 children with selective mutism. J Am Acad Child Adolesc Psychiatry 1997 36 653 660
  31. 31. Dilbaz N. Güz H. Liebowitz Social Anxiety Rating Scale: Turkish reliability and Validity. 37. National Psychiatry Congress, İstanbul, 2 6October 2001
  32. 32. Dilbaz N. The prevelance of social phobia among the Turkish university students. XII. World Congress of Psychiatry, Yokohama, August 24 29 2002
  33. 33. Dilbaz N. Güz H. The gender differences in Social Phobia. (Sosyal kaygı bozukluğunda cinsiyet farklılıkları. Nöropsikiyatri Arşivi ) Neuropsychiatry Archives 2002 39 79 86Turkish)
  34. 34. Dilbaz N. Treatment of Social Anxiety Disorders. Dilbaz N (ed.) Recent Advances in Anxiety Disorders. Ankara; Pozitif Matbaacılık, 2005Turkish)
  35. 35. Emmanuel N. Johnson M. Villareal G. et al. Imipramine in the Treatment of Social Phobia, A Double-Blind Study. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology. 8-12-1997Kohala Coast, Hawaii.
  36. 36. Emmanuel N. P. Brawman-Mintzer O. Morton W. A. Book S. W. Johnson M. R. Lorberbaum J. P. Ballenger J. C. Lydiard R. B. Bupropion-S R. in treatment. of social. phobia Depress Anxiety. 2000 12 2 111 3
  37. 37. BA Erwin Heimberg. R. G. Juster H. Mindlin M. Comorbid anxiety and mood disorders among persons with social anxiety disorder Behaviour Research and Therapy 2002 40 19 35
  38. 38. CA Essau Conradt. J. Petermann F. Frequency and comorbidity of social phobia and social fears in adolescents. Behav Res 1999 37 831 43
  39. 39. Federoff I. C. Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001 21 311 24
  40. 40. Fehm L. Pelissolo A. Furmark T. Wittchen H. U. Size and burden of social phobia in Europe. European Neuropsychopharmacology 2005 15 453 462
  41. 41. Flannery-Schroeder E. C. Kendall P. Group and individual cognitive-behavioral treatments for youth with anxiety disorders: a randomized clinical trial. Cognit Ther Res 2000 24 251 78
  42. 42. Furmark T. Tillfors M. Garpenstrand H. Marteinsdottir I. Langstrom B. Oreland L. Fredrikson M. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 2004 362 189 192
  43. 43. Furmark T. Neurobiological aspects of social anxiety disorder. Isr J Psychiatry Relat Sci. 2009 46 1 5 12
  44. 44. Gelernter C. S. Uhde T. W. Cimbolic P. et al. Cognitive behavioural and pharmacological treatment of social phobia: a controlled study. Arch Gen Psychiatry 1991 48 938 45
  45. 45. Gould R. Otto M. Pollack M. Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: a metaanalysis. Clin Psychol Sci Pract 1997
  46. 46. Graeff FG.On serotonin and experimental anxiety. Psychopharmacology 2002 163 467 476
  47. 47. Grant B. F. DS Hasin Blanco. C. et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 2005 66 1351 1361
  48. 48. Grant KA, Shively CA, Nader MA, Ehrenkaufer RL, Line SW, Morton TE, Gage HD, Mach RH.Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse 1998 29 80 83
  49. 49. Hariri A. R. Holmes A. Genetics of emotional regulation: Th e role of the serotonin transporter in neural function. Trends Cogn Sci 2006 10 182 191
  50. 50. Heimberg R. G. Stein M. B. Hiripi E. et al. Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades.Eur Psychiatry 2000 15 29 37
  51. 51. Hirshfeld-Becker D. R. Biederman J. Henin A. Faraone S. V. Davis S. Harrington K. Rosenbaum J. F. Behavioral Inhibition in Preschool Children At Risk Is a Specific Predictor of Middle Childhood Social Anxiety: A Five year Follow-up. J Dev Behav Pediatr 2007 28 225 233
  52. 52. Hope DA, Heimberg RG, Bruch MA.Dismantling cognitive behavioral group therapy for social phobia. Behav Res Ther 1995 33 637 50
  53. 53. Ipser JC, Kariuki CM, Stein DJ.Pharmacotherapy for social anxiety disorder: A systematic review. Expert Rev Neurother 2008 8 235 257
  54. 54. Jackson A. State-dependent effects of atypical benzodiazepine receptor agonists. Psychopharmacology 1995 119 4 399 404
  55. 55. Katzelnick DJ, Greist JH. Social anxiety disorder: an unrecognized problem in primary care. J Clin Psychiatry 2001Suppl.): 11 6
  56. 56. Katzelnick DJ, Kobak KA, Greist JH, et al.Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995 152 1368 71
  57. 57. Keith J. R. Pitts R. C. Pezzuit T. et al. Effects of positive GABA (A) modulators on a multiple-component, repeated-acquisition test of spatial learning. Behav Pharmacol 2003 14 1 67 75
  58. 58. Kessler R. C. Crum R. M. Warner L. A. Nelson C. B. Schulenberg J. Anthony J. C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997 54 313 321
  59. 59. Kessler R. C. Stang P. Wittchen H. U. Stein M. EE Walters Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey. Psychological Medicine 1999 29 555 567
  60. 60. Kessler R. C. Berglund P. Demler O. Jin R. Merikangas K. R. Walters E. E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005 6 593 602
  61. 61. Kumpulainen K. Rasanen E. Raaska H. Somppi V. Selective mutism among second-graders in elementary school. Eur Child Adolesc Psychiatry 1998 7 24 29
  62. 62. Lanzenberger R. R. Mitterhauser M. Spindelegger C. Wadsak W. Klein N. Mien L. K. Holik A. Attarbaschi T. Mossaheb N. Sacher J. Geiss-Granadia T. Kletter K. Kasper S. Tauscher J. Reduced serotonin. receptor A. binding in. social anxiety. disorder Biol Psychiatry 2007 61 1081 1089
  63. 63. Lecrubier Y. Weiller E. Comorbidities in social phobia. International Clinical Psychopharmacology 12 (suppl. 6) 1997 17 21
  64. 64. Lewinsohn P. M. Hops H. Roberts R. E. et al. Adolescent psychopathology. I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psych 1993 102 133 44
  65. 65. Liebowitz M. R. De Martinis N. A. Weihs K. et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003 64 7 785 92
  66. 66. Liebowitz M. R. Gelenberg A. J. Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 62 190 198
  67. 67. Liebowitz M. R. Schneier F. Campeas R. et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992 49 290 300
  68. 68. Liebowitz M. R. Stein M. B. Tancer M. et al. A. randomised double-blind. fixed-dose comparison. of paroxetine. placebo in. the treatment. of generalized. social anxiety. disorder J Clin Psychiatry 2002 63 66 74
  69. 69. Liebowitz MR. Social phobia.Mod Probl Pharmacopsychiatry 1987 22 141 73
  70. 70. Mancini C. Van Ameringen M. Oakman J. M. Farvolden P. Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depress Anxiety 1999 10 33 39
  71. 71. March Wells J. K. Combining medication and psychotherapy. In: Martin A, Scahill L, Charney DS, et al., editors. Pediatric psychopharmacology: principles and practice. New York: Oxford University Press, 2003 2003 426 46
  72. 72. Mennin DS, Heimberg RG,Jack MS.Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response. J Anxiety Disord. 2000 14 4 325 43
  73. 73. Merikangas K. R. Angst J. Comorbidity and social phobia: evidence from clinical, epidemiologic and genetic studies. Archives of Psychiatry and Clinical Neuroscience 1995
  74. 74. Meron Ruscio. A. Brown T. A. Chiu W. T. Sareen J. Stein M. B. Kessler R. C. Social fears and social phobia in theUnited States: Results from the National Comorbidity Survey Replication. Psychol Med 2008 38 15 28
  75. 75. Morris EP, Stewart SH, Ham LS.The relationship between social anxiety disorder and alcohol use disorders: a critical review. Clin Psychol Rev 2005 25 734 760
  76. 76. Mörtberg E. Mirtazapine reduces social anxiety and improves quality of life in women with social phobia. Evid Based Ment Health. 2006
  77. 77. Mrakotsky C. Masek B. Biederman J. Raches D. Hsin O. Forbes P. de Moor C. De Maso D. R. Gonzalez-Heydrich J. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008 22 1 88 97
  78. 78. Naranjo CA, Knoke DM.The role of selective serotonin- reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry 2001Suppl.): 18S-25S.
  79. 79. Pallanti S. Querciolo L. Rossi A. et al. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry 1999 60 819 23
  80. 80. Pande AC, Davidson JR, Jeff erson JW, et al.Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999 19 341 348
  81. 81. Pande AC, Feltner DE, Jeff erson JW, et al.Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol 2004 24 141 149
  82. 82. Pini S. Cassano G. B. Simonini E. Savino M. Russo A. Montgomery S. A. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. Journal of Affective Disorders 1997
  83. 83. Prior M. Smart D. Sanson A. et al. Does shy-inhibited temperament in childhood lead to anxiety problems in adolescence? J Am Acad Child Adolesc Psychiatry 2000 39 461 468
  84. 84. Richard I. H. Schiff er. R. B. Kurlan R. Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996 8 383 392
  85. 85. Robinson H. M. Hood S. D. A. review of. Pharmacological treatments. Curr Psychiatry Reviews 2007 3 95 122
  86. 86. Schneier F. R. Johnson J. Hornig C. D. et al. Social phobia. comorbidity morbidity in. an epidemiologic. sample Arch Gen Psychiatry 1992 49 282 8
  87. 87. Schneier F. R. Liebowitz M. R. Abi-Dargham A. Zea-Ponce Y. Lin-H S. Laruelle M. Low dopamine. D. receptor binding. potential in. social phobia. Am J Psychiatry 2000 157 457 459
  88. 88. Schneier F. R. Spitzer R. L. Gibbon M. Fyer A. J. Liebowitz M. R. The relationship of social phobia subtypes and avoidant personality disorder. Compr Psychiatry 1991 32 496 502
  89. 89. Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG.Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010 25 5 302 4
  90. 90. Schutters SI, van Megen HJ, Westenberg HG.Efficacy of quetiapine in generalized social anxiety disorder: Results from an open-label study. J Clin Psychiatry 2005 66 540 542
  91. 91. Serretti A. Calati R. Mandelli L. De Ronchi D. Serotonin transporter gene variants and behavior: A comprehensive review. Curr Drug Targets 2006 7 1659 1669
  92. 92. Sheehan D. V. Harnett-Sheehan K. BA Raj The measurement of disability. Int Clin Psychopharmacol 1996Suppl. 3: 89S-95S.
  93. 93. Simpson HB, Schneier FR, Campeas RB, et al.Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998 18 132 135
  94. 94. Smolka M. N. Schumann G. Wrase J. Grusser S. M. Flor H. Mann K. Braus D. F. Goldman D. Buchel C. Heinz A. Catechol Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 2005 25 836 842
  95. 95. Stein D. J. Cameron A. Amrein R. et al. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002Jul; 17 4 161 70
  96. 96. Stein D. J. Kasper S. Andersen E. W. et al. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety 2005 20 4 175 81
  97. 97. Stein DJ.Algorithm for the pharmacotherapy of anxiety disorders. Curr Psychiatry Rep 2003
  98. 98. Stein MB, Fyer AJ, Davidson JRT, et al.Fluvoxamine treatment of social phobia (social anxiety disorder): a double blind placebo-controlled study. Am J Psychiatry 1999 156 756 60
  99. 99. Stein M. B. Gelernter J. Smoller J. W. Genetics of social anxiety disorder and related traits. In: Bandelow B, Stein DJ, editors. Social anxiety disorder. New York: Marcel Dekker, 1994 197 214
  100. 100. Stein MB, Liebowitz MR, Lydiard RB, et al.Paroxetine in the treatment of generalized social phobia (social anxiety disorder): a randomised, double-blind, placebo-controlled study JAMA 1998 280 708 13
  101. 101. Steinhausen H. C. Juzi C. Selective mutism. an analysis. of 1. cases Juzi C. Selective mutism: an analysis of 100 cases. J Am Acad Child Adolesc Psychiatry 1996 35 606 14
  102. 102. Stern R. G. Petti T. A. Bopp K. Tobia A. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol. 2009 29 3 206 9
  103. 103. Tancer ME.Neurobiology of social phobia. J Clin Psychiatry 1993suppl 12 26 30
  104. 104. Thase M. E. Recognition and diagnosis of atypical depression. Journal of Clinical Psychiatry 2007Suppl. 8), 11-16.
  105. 105. Tiihonen J. Kuikka J. Bergstrom K. Lepola U. Koponen H. Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997 154 239 242
  106. 106. Tillfors M. Ekselius L. Social Phobia and Avoidant Personality Disorder: Are They Separate Diagnostic Entities or Do They Reflect a Spectrum of Social Anxiety? Isr J Psychiatry Relat Sci 2009 46 25 33
  107. 107. Turner SM, Beidel DC,Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994 62 350 358
  108. 108. Vaishnavi S. Alamy S. Zhang W. Connor K. M. Davidson J. R. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007 31 7 1464 9
  109. 109. Van Ameringen M. Mancini C. Pipe B. Bennett M. Optimizing treatment in social phobia: A review of treatment resistance. CNS Spectr 2004 9 753 762
  110. 110. Van Ameringen MA, Lane RM, Walker JR, et al.Sertraline treatment of generalized social phobia: a 20-week, double- blind, placebo-controlled study. Am J Psychiatry 2001 158 275 81
  111. 111. Van Vliet IM, den Boer JA, Westenberg HGM.Psycho-pharmacological treatment of social phobia: a double-blind, placebo.controlled study with fluvoxamine. Psychopharmacology (Berl) 1994 115 128 34
  112. 112. Versiani M. Nardi A. E. Mundim F. D. et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992 161 353 60
  113. 113. Vulink N. C. Figee M. Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol. 2011Feb 21. [Epub ahead of print]
  114. 114. Wittchen H. U. Nelson C. B. Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychol Med 1998 28 109 26
  115. 115. Wlazlo Z. Schroeder-Hartwig K. Hand I. Kaiser G. Munchau N. Exposure in vivo vs social skills training for social phobia: long-term outcome and differential effects. Behav Res Ther 1990
  116. 116. Wren F. J. Scholle S. H. Heo J. et al. Pediatric mood and anxiety syndromes in primary care: who gets identified. Int J Psychiatry Med 2003 33 1 16
  117. 117. Zaider TI, Heimberg RG.Non-pharmacologic treatments for social anxiety disorder. Acta Psychiatr Scand Suppl 2003S-84S
  118. 118. Zhang W. Connor K. M. Davidson J. R. Levetiracetam in social phobia: A placebo controlled pilot study. J Psychopharmacol 2005 19 551 553

Written By

Nesrin Dilbaz, Aslı Enez and Serçin Yalçın Çavus

Submitted: 03 November 2010 Published: 12 September 2011